AbCellera Biologics Inc vs Kimberly Clark Corp — how do they compare? AbCellera Biologics Inc trades at $9.03 (market cap $2.99B), while Kimberly Clark Corp trades at $108.57 (market cap $36.11B). The key difference: Kimberly Clark Corp is far larger — about 12.1× AbCellera Biologics Inc's market cap, and Kimberly Clark Corp pays a 4.72% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | KMB | |
|---|---|---|
Market Cap | $2.99B | $36.11B |
Sector | Health | Consumer Staples |
52-Week High | $9.76 | $134.81 |
52-Week Low | $2.78 | $93.05 |
Enterprise Value | $2.58B | $41.67B |
Dividend Yield | — | 4.72% |
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →